摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

diiodobis(tetrahydrothiophene)palladium(II) | 26923-67-1

中文名称
——
中文别名
——
英文名称
diiodobis(tetrahydrothiophene)palladium(II)
英文别名
trans-[PdI2(tetramethylene sulphide)2]
diiodobis(tetrahydrothiophene)palladium(II)化学式
CAS
26923-67-1
化学式
C8H16I2PdS2
mdl
——
分子量
536.576
InChiKey
QBQLKWBLEYJJNQ-UHFFFAOYSA-L
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.8
  • 重原子数:
    13.0
  • 可旋转键数:
    2.0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    0.0
  • 氢给体数:
    0.0
  • 氢受体数:
    0.0

反应信息

  • 作为产物:
    描述:
    四氢噻吩 、 potassium tetraiodopalladate(II) 以 为溶剂, 以71%的产率得到diiodobis(tetrahydrothiophene)palladium(II)
    参考文献:
    名称:
    钯(II)和铂(II)配合物中配体环大小的变化对硫反型势垒的影响。动态氢1核磁共振研究
    摘要:
    该系列复合物的反式- [MX 2 {[图形省略] R 2)Ñ } 2 ](M =钯II或Pt II ; X =氯,溴,或I; R = H和/或Me; ñ = 2 –5)已合成,并且已通过带形拟合方法对它们的可变温度nmr光谱进行了精确分析,以确定在硫原子处发生金字塔倒置的势垒。氯配合物中的势垒能比相应的溴化物高2–3 kJ mol –1,而溴化物则为4–5 kJ mol –1高于碘复合物。金字塔形反转能量非常依赖于配体环的大小。五元环和六元环的那些与线性硫化物的配合物相当,但是四元环的配合物显示出金字塔形硫转化阻挡层的显着提高。对于三元环硫化物的络合物,直到分解开始的温度都没有检测到反转,这是在二烷基硫化物金属络合物中这种刚性的第一个报道实例。
    DOI:
    10.1039/dt9790001994
点击查看最新优质反应信息

文献信息

  • Elding, L. I.; Noren, B.; Oskarsson, A., Zeitschrift fur Kristallographie
    作者:Elding, L. I.、Noren, B.、Oskarsson, A.、Svensson, C.
    DOI:——
    日期:——
  • <i>trans</i> influence on bond distances. Structures of <i>trans</i>-diiodobis(tetrahydrothiophene)palladium(II) and <i>trans</i>-diiodobis(tetrahydrothiophene)platinum(II)
    作者:Å. Oskarsson、B. Norén、C. Svensson、L. I. Elding
    DOI:10.1107/s010876819000622x
    日期:1990.12.1
    Crystals of trans-diiodobis(tetrahydrothiophene)-palladium(II) and trans-diiodobis(tetrahydrothiophene)platinum(II) were prepared by dissolving the appropriate metal iodide in tetrahydrothiophene at 353 K and cooling to room temperature. Crystal data at room temperature (Mo K-alpha, lambda = 0.7107-angstrom) are: [PdI2(C4H8S)2], M(r) = 536.54, triclinic, P1BAR, a = 8.4920 (8), b = 8.8248 (1), c = 9.4580 (11) angstrom, alpha = 97.595 (9), beta = 91.963 (9), gamma = 99.482 (9)-degrees, V = 691.8 (1) angstrom-3, Z = 2, D(x) = 2.576 Mg m-3, mu = 5.997 mm-1, F(000) = 496, R = 0.028 for 2090 unique reflections with I > 3-sigma-(I); [PtI2(C4H8S)2], M(r) = 625.24, triclinic, P1BAR, a = 7.889 (2), b = 8.676 (1), c = 10.616 (2) angstrom, alpha = 103.75 (1), beta = 90.36 (1), gamma = 94.70 (2)-degrees, V = 703.2 (2) angstrom-3, Z = 2, D(x) = 2.953 Mg m-3, mu = 14.67 mm-1, F(000) = 560, R = 0.024 for 3988 reflections with I > 3-sigma-(I). Both compounds consist of van-der-Waals-packed mononuclear trans-[MI2(C4H8S)2] complexes. There are two centrosymmetric metal complexes in the asymmetric unit of the Pt compound but only one pseudoplanar complex in the Pd compound. The acceptor-donor distances are Pd-I 2.603 (1), 2.625 (1); Pd-S 2.316 (2), 2.329 (2); Pt-I 2.606 (1), 2.616 (1); and Pt-S 2.309 (1), 2.310 (1) angstrom. A literature survey of compounds in which ligand-I or -S (in thioethers) atoms are trans to themselves shows average M-I and M-S distances of Pd-I 2.605 (20), Pd-S 2.324 (15), Pt-I 2.609 (9) and Pt-S 2.313 (13) angstrom. The spread of the M-I and M-S distances is significantly increased if complexes are included where I or S are not trans to themselves, indicating that for some donor atoms the trans influence dominates over other factors such as the cis influence and packing forces.
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)